{"id":"NCT00129220","sponsor":"Eli Lilly and Company","briefTitle":"Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder","officialTitle":"Placebo- and Haloperidol-Controlled Double-Blind Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2005-08-11","resultsPosted":"2010-02-15","lastUpdate":"2010-12-28"},"enrollment":224,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"olanzapine","otherNames":["LY170053","Zyprexa"]},{"type":"DRUG","name":"haloperidol","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Olanzapine","type":"EXPERIMENTAL"},{"label":"Haloperidol","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to confirm the efficacy of olanzapine in the treatment of manic or mixed symptoms associated with bipolar I disorder.","primaryOutcome":{"measure":"Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score","timeFrame":"Baseline, 3 weeks","effectByArm":[{"arm":"Olanzapine","deltaMin":-12.6,"sd":10},{"arm":"Haloperidol","deltaMin":-14.3,"sd":11.4},{"arm":"Placebo","deltaMin":-6.8,"sd":14}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":["22134043"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":105},"commonTop":["Somnolence","Nasopharyngitis","Thirst","Constipation","Weight increased"]}}